ArticleVirus evolution2026
Coxsackievirus A6 was the predominant pathogen of hand, foot, and mouth disease with frequent recombination and mutations in Shandong Province, 2023.
Article in Virus evolution, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hand, Foot, and Mouth Disease Surveillance in Anhui, After Introduction of the Enterovirus 71 Vaccine and During the COVID-19 Pandemic: Ecological Interrupted Time Series Study.JMIR public health and surveillance · 2026Article
- Serotypes distribution characteristic of enterovirus in sewage in Hangzhou, Zhejiang Province from January 2023 to December 2024.Virology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogens of hand, foot, and mouth disease (HFMD) are changing, with CV-A6 becoming the predominant one and evolving rapidly. We collected data on monthly HFMD infections per county and related demographic variables in Shandong Province, China, during 2023. Viruses were isolated and sequenced for further bioinformatics analysis. An epidemiological follow-up study in Jinan city was conducted to explore the relationship between onychomadesis and CV-A6. The risk factors of atypical skin lesions were analysed using binary logistic regression models. Totally, 47 396 cases were clinically diagnosed as HFMD, among which 9543 samples were collected and 7133 (74.75%) were laboratory-confirmed Enterovirus (EV)-positive cases. CV-A6 became the predominant pathogen (5993, 84.02%). Forty-six representative CV-A6 strains were successfully isolated; by successfully constructing a novel amplicon-based next-generation sequencing method, the full genomes of the 46 strains were sequenced. All strains belonged to the D3c subgenotype. A new recombination lineage emerged with three specific amino acid mutations in the P3 region. Fourteen amino acid sites in the P3 coding region and three in the VP1 coding region were identified as highly variable amino acid sites. On the whole, viral evolution was predominantly driven by negative selection. Three amino acid sites in the VP1 coding region and one in the P3 coding region were under positive selection, among which P3-551 was both a highly variable amino acid site and underwent positive selection pressure. CV-A6 strains in Shandong, 2023, may have originated from Southwest China lineages, which emerged from Vietnam. CV-A6 was the primary pathogen of onychomadesis and atypical skin lesions. The increase in age, male individuals, living in suburban areas, with fever and respiratory symptoms were significant risk factors for atypical skin lesions. In 2023, CV-A6 was the predominant pathogen of HFMD in Shandong and underwent rapid evolution with frequent recombination and mutations. Therefore, surveillance for disease prevention and control should be strengthened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.